thor: erdafitinib in advanced or metastatic urothelial cancer and fgfr alterations
Published 1 year ago • 85 plays • Length 1:04Download video MP4
Download video MP3
Similar videos
-
1:47
thor: erdafitinib in metastatic urothelial cancer with fgfr alterations
-
3:37
phase iii thor study: erdafitinib vs. pembrolizumab in fgfr-altered advanced or metastatic uc
-
2:31
an update on erdafitinib for metastatic/uresectable fgfr alteration urothelial carcinoma
-
1:49
thor: impact of fgfr3 alterations in muc on subtype and outcomes with erdafitinib vs pembrolizumab
-
1:47
the future role of erdafitinib in advanced urothelial carcinoma
-
1:27
thor-2 cohort 3 interim analysis: erdafitinib in intermediate-risk nmibc with fgfr3/2 alterations
-
1:49
blc2001: erdafitinib for the treatment of metastatic urothelial carcinoma
-
2:20
erdafitinib /- cetrelimab in muc patients with fgfr alterations
-
3:42
norse: erdafitinib cetrelimab in muc with fgfr alterations
-
4:47
asco 2023 highlights on erdafitinib in metastatic urothelial cancer with select fgfr alterations
-
5:14
erdafitinib demonstrates efficacy in intermediate-risk nmibc with fgfr alterations
-
3:49
phase 3 thor study results: erdafitinib vs. chemotherapy in advanced urothelial cancer | crsf 2024
-
0:49
evolving landscape of urothelial cancer treatment: erdafitinib or enfortumab vedotin?
-
2:47
#esmo21 highlights on erdafitinib in adv. urothelial cancer with fgfra alterations: the norse study
-
1:27
erdafitinib and enfortumab vedotin in pretreated fgfr2/3-mutant bladder cancer
-
2:33
ragnar study evidences efficacy and safety of erdafitinib in patients with advanced fgfr malign...
-
2:12
erdafitinib: one more tool for bladder cancer
-
11:42
fgfr inhibitors in bladder cancer: testing, screening and highlights from asco 2020
-
1:17
recent treatment approvals for metastatic and advanced urothelial carcinoma